Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00042560-199803010-00009PMID 9495224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group.

  1997cited by this paper
• Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.

  1997cited by this paper
• Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals

  1996cited by this paper
• Use of observational data, including surveillance studies, for evaluating AIDS therapies.

  1996cited by this paper
• Therapy for human immunodeficiency virus infection -- what have we learned?

  1996cited by this paper
• Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

  1996cited by this paper
• A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

  1996cited by this paper
• Survival in HIV-Infected Patients Who Have Received Zidovudine: Comparison of Combination Therapy with Sequential Monotherapy and Continued Zidovudine Monotherapy

  1996cited by this paper
• Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter

  1996cited by this paper
• Survivor Treatment Selection Bias in Observational Studies: Examples from the AIDS Literature

  1996cited by this paper
• Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.

  1996cited by this paper
• Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.

  1996cited by this paper
• Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel

  1996cited by this paper
• Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group.

  1994cited by this paper
• Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine

  1994cited by this paper
• The need for randomization in the study of intended effects.

  1983cited by this paper

• Hematological and clinical profiles of HIV-infected adults initiating Highly Active AntiRetroviral Therapy (Haart) in Uganda

  2015cites this paper
• The effects of highly active antiretroviral therapy on survival and CD4 cell percentage in HIV-infected children in Kinshasa, Democratic Republic of Congo

  2011influential citation
• GENERAL REMARKS ON THE SUBSTANCES CONSIDERED

  2008cites this paper
• Current Hemoglobin Levels Are More Predictive of Disease Progression Than Hemoglobin Measured at Baseline in Patients Receiving Antiretroviral Treatment for HIV Type 1 Infection

  2007cites this paper
• Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future

  2006cites this paper
• Disease management--constructing optimal NRTI-based combinations: past, present, and future.

  2006cites this paper
• Prolonged survival of end-stage AIDS patients immunized with therapeutic HIV vaccine V-1 Immunitor.

  2005cites this paper
• Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV.

  2004cites this paper
• AIDS-defining illnesses among patients with HIV in Singapore, 1985 to 2001: results from the Singapore HIV Observational Cohort Study (SHOCS)

  2004cites this paper
• Dual Nucleoside Therapy for HIV Infection: Analysis of Results and Factors Influencing Viral Response and Long Term Efficacy

  2003cites this paper
• The impact of the M184V substitution in HIV‐1 reverse transcriptase on treatment response

  2002cites this paper
• Update on Didanosine

  2002cites this paper
• Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study

  2002cites this paper
• Response to Antiretroviral Therapy among Patients Exposed to Three Classes of Antiretrovirals: Results from the Eurosida Study

  2002cites this paper
• Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.

  2001cites this paper
• Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir

  2001cites this paper
• Palliative care for HIV disease in the era of highly active antiretroviral therapy

  2000cites this paper
• Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

  2000cites this paper
• AIDS across Europe, 1994-98: the EuroSIDA study.

  2000cites this paper
• Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups.

  1999cites this paper
• Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group.

  1999cites this paper
• Changing treatment patterns among patients with HIV: Royal Free Hospital 1987–97

  1999cites this paper
• Regional survival differences across Europe in HIV-positive people: the EuroSIDA study.

  1999cites this paper
• Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

  1998cites this paper